Search
Crovalimab
go.drugbank.com/drugs/DB16128ApprovedInvestigational[L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Carbinoxamine
go.drugbank.com/drugs/DB00748ApprovedThe product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many … This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
Levetiracetam
go.drugbank.com/drugs/DB01202ApprovedInvestigationalLevetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically un...
Products: 6-URPatisiran
go.drugbank.com/drugs/DB14582ApprovedIt is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220].
Nitrendipine
go.drugbank.com/drugs/DB01054ApprovedWithdrawnNitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natri...
Nicardipine
go.drugbank.com/drugs/DB00622ApprovedInvestigationalA potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the ...
Belimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigationalIt is produced by recombinant DNA technology in a murine cell (NS0) expression system. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.
Lercanidipine
go.drugbank.com/drugs/DB00528ApprovedInvestigationalWithdrawnLercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigational[A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. … [A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until
Sufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalIt is administered by the intravenous, epidural and sublingual routes. … Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately [L4718].